IP Library Granted Patent US 11,524,072
Granted Patent B2
US 11,524,072 · App. 17/061,696 · Granted Dec 13, 2022

Vaccine delivery method

Inventors: Donald A. Harn (Athens, GA); Rafaella Queiroz (Minas Gerais, BR); Lisa Shollenberger (Norfolk, VA); Emily-Joy Farah Samli (Athens, GA)
Assignee: University of Georgia Research Foundation, Inc.
A61K39/39A61K9/0019A61K9/06A61K39/00A61K39/0003A61K39/012A61K39/0208A61K39/0258A61K39/0275A61K39/04A61K39/05A61K39/08A61K39/085A61K39/092A61K39/099A61K39/102A61K39/104A61K39/1045A61K39/12A61K39/145A61K39/15A61K39/155A61K39/17A61K39/215A61K39/255A61K39/265A61K39/29A61K39/292A61K47/42A61K2039/5252A61K2039/53A61K2039/54A61K2039/545A61K2039/552A61K2039/55505A61K2039/55516A61K2039/55555A61K2039/55561A61K2039/55566A61K2039/575C12N2710/16334C12N2710/16734C12N2710/24034C12N2720/10034C12N2720/12334C12N2730/10134C12N2750/10034C12N2750/14334C12N2760/16134C12N2760/16171C12N2760/18034C12N2760/18134C12N2770/10034C12N2770/20034C12N2770/24334C12N2770/32334Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,524,072
App. No.
17/061,696
Granted
Dec 13, 2022
Kind
B2
Abstract

A vaccine delivery method is presented that includes a composition including as one component a slurry matrix that is a liquid at room temperature and a gel at physiological pH, physiological salt concentrations and/or physiological temperatures and as a second component one or more antigens. Also included are methods of inducing an immune response in a subject and vaccinating a subject by administering such compositions.

Claims (10)

1. A vaccine composition comprising a peptide hydrogel of the peptide scaffold RADARADARADARADA (SEQ ID NO:2), an influenza antigen, and a TLR9 agonist, wherein the vaccine composition is a liquid at room temperature, non-physiological pH, and/or non-physiological salt concentrations and a gel at physiological pH, physiological salt concentrations and/or physiological temperatures, and wherein the vaccine composition gels after administration to a subject.

2. The vaccine composition of claim 1 , wherein the TLR9 agonist comprises a CpG oligodeoxynucleotide (ODN).

3. The vaccine composition of claim 1 , wherein the influenza antigen comprises an influenza A, influenza B, or influenza C antigen.

4. The vaccine composition of claim 1 , wherein the influenza antigen comprises a recombinant nucleoprotein (rNP) influenza virus antigen.

5. The vaccine composition of claim 1 , wherein the influenza antigen comprises a whole-inactivated influenza virus.

6. The vaccine composition of claim 1 , wherein the vaccine composition is lyopholized.

7. A method of producing an immune response in a subject, the method comprising administering a vaccine composition of claim 1 to the subject.

8. A method of vaccinating a subject to influenza, the method comprising administering a vaccine composition of claim 1 to the subject.

9. The method of claim 7 , wherein the subject is human.

10. The method of claim 7 , wherein administration of the composition comprises subcutaneous (sc) delivery, intramuscular (im) delivery, intradermal delivery, transdermal delivery, mucosal delivery, intravaginal delivery, intrarectal delivery, intraperitoneal delivery, inhalation delivery, and/or aerosol delivery.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2021
From: SHOLLENBERGER, LISA
To: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
Reel/Frame 058317/0551 →
Continuity (5)
Continuation 15411083 · Jan 20, 2017
Continuation 13793329 · Mar 11, 2013
Continuation In Part PCTUS2012034012 · Apr 18, 2012
Provisional Application 61476431 · Apr 18, 2011
Related Publication 20210015916A1 · Jan 21, 2021
Cited By (1)
US 12,186,390